Laboratory Of America Holdings Enhances Colorectal Cancer Genetic Testing Through New Clinical Trial

Laboratory Of America Holdings (LH) collaborates with the Alliance for Clinical Trials in Oncology to enhance genetic testing for colorectal cancer, addressing a critical gap in patient care. The national multicenter clinical trial focuses on boosting germline genetic testing among at-risk family members and assessing the impact of multigene panel testing on newly diagnosed colorectal cancer patients.

Proactive Outreach to Increase Testing Participation

With inherited variants accounting for nearly 10% of colorectal cancer cases, the initiative highlights the importance of proactive genetic testing, as fewer than one-third of at-risk relatives currently receive the necessary tests. The trial aims to examine whether outreach from healthcare providers can significantly improve testing participation rates among first-degree relatives of affected patients.

Exclusive Testing Provider and Expected Outcomes

Spearheaded with sponsorship from the National Cancer Institute (NCI), the trial will integrate Labcorp’s Invitae testing services as the exclusive genetic testing provider. This collaboration is expected to generate valuable real-world evidence on how healthcare providers can facilitate genetic testing and improve follow-up care for families at risk. The overall results might reshape how genetic testing information is communicated, ultimately leading to better health outcomes for patients with hereditary cancer syndromes across the nation.

Transforming Patient Care and Awareness

This initiative is not only significant in advancing genetic testing methodologies but also plays a vital role in raising awareness about inherited cancer risks among affected families. By emphasizing the importance of genetic evaluations, Laboratory Of America Holdings is poised to make a meaningful impact on patient care standards in the oncology field.